Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Paclitaxel-loaded biodegradable ROS-sensitive nanoparticles for cancer therapy

AD. Pandya, E. Jäger, S. Bagheri Fam, A. Höcherl, A. Jäger, V. Sincari, B. Nyström, P. Štěpánek, T. Skotland, K. Sandvig, M. Hrubý, GM. Mælandsmo,

. 2019 ; 14 (-) : 6269-6285. [pub] 20190806

Language English Country New Zealand

Document type Journal Article

Background: Reactive oxygen species (ROS), such as hydrogen peroxide and superoxide, trigger biodegradation of polymer-based nanoparticles (NPs) bearing pinacol-type boronic ester groups. These NPs may selectively release their cargo, in this case paclitaxel (PTX), at the high levels of ROS present in the intracellular environment of inflamed tissues and most tumors. Purpose: The main objective was to determine anti-tumor efficacy of PTX-loaded ROS-sensitive NPs and to examine whether macrophage infiltration had any impact on treatment efficacy. Methods: NPs were synthesized and their characteristics in the presence of H2O2 were demonstrated. Both confocal microscopy as well as flow cytometry approaches were used to determine degradation of ROS-sensitive NPs. HeLa cells were cultured in vitro and used to establish tumor xenografts in nude mice. In vivo experiments were performed to understand toxicity, biodistribution and anti-tumor efficacy of the NPs. Moreover, we performed immunohistochemistry on tumor sections to study infiltration of M1 and M2 subsets of macrophages. Results: We demonstrated that PTX delivered in NPs containing a ROS-sensitive polymer exhibits a better anti-tumor efficacy than PTX in NPs containing ROS-non-sensitive polymer, free PTX or Abraxane® (nab-PTX). The biodistribution revealed that ROS-sensitive NPs exhibit retention in liver, spleen and lungs, suggesting a potential to target cancer metastasizing to these organs. Finally, we demonstrated a correlation between infiltrated macrophage subsets and treatment efficacy, possibly contributing to the efficient anti-tumor effects. Conclusion: Treatment with ROS-sensitive NPs containing PTX gave an improved therapeutic effect in HeLa xenografts than their counterpart, free PTX or nab-PTX. Our data revealed a correlation between macrophage infiltration and efficiency of the different antitumor treatments, as the most effective NPs resulted in the highest infiltration of the anti-tumorigenic M1 macrophages.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19044542
003      
CZ-PrNML
005      
20200114152354.0
007      
ta
008      
200109s2019 nz f 000 0|eng||
009      
AR
024    7_
$a 10.2147/IJN.S208938 $2 doi
035    __
$a (PubMed)31496685
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a nz
100    1_
$a Pandya, Abhilash D $u Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway.
245    10
$a Paclitaxel-loaded biodegradable ROS-sensitive nanoparticles for cancer therapy / $c AD. Pandya, E. Jäger, S. Bagheri Fam, A. Höcherl, A. Jäger, V. Sincari, B. Nyström, P. Štěpánek, T. Skotland, K. Sandvig, M. Hrubý, GM. Mælandsmo,
520    9_
$a Background: Reactive oxygen species (ROS), such as hydrogen peroxide and superoxide, trigger biodegradation of polymer-based nanoparticles (NPs) bearing pinacol-type boronic ester groups. These NPs may selectively release their cargo, in this case paclitaxel (PTX), at the high levels of ROS present in the intracellular environment of inflamed tissues and most tumors. Purpose: The main objective was to determine anti-tumor efficacy of PTX-loaded ROS-sensitive NPs and to examine whether macrophage infiltration had any impact on treatment efficacy. Methods: NPs were synthesized and their characteristics in the presence of H2O2 were demonstrated. Both confocal microscopy as well as flow cytometry approaches were used to determine degradation of ROS-sensitive NPs. HeLa cells were cultured in vitro and used to establish tumor xenografts in nude mice. In vivo experiments were performed to understand toxicity, biodistribution and anti-tumor efficacy of the NPs. Moreover, we performed immunohistochemistry on tumor sections to study infiltration of M1 and M2 subsets of macrophages. Results: We demonstrated that PTX delivered in NPs containing a ROS-sensitive polymer exhibits a better anti-tumor efficacy than PTX in NPs containing ROS-non-sensitive polymer, free PTX or Abraxane® (nab-PTX). The biodistribution revealed that ROS-sensitive NPs exhibit retention in liver, spleen and lungs, suggesting a potential to target cancer metastasizing to these organs. Finally, we demonstrated a correlation between infiltrated macrophage subsets and treatment efficacy, possibly contributing to the efficient anti-tumor effects. Conclusion: Treatment with ROS-sensitive NPs containing PTX gave an improved therapeutic effect in HeLa xenografts than their counterpart, free PTX or nab-PTX. Our data revealed a correlation between macrophage infiltration and efficiency of the different antitumor treatments, as the most effective NPs resulted in the highest infiltration of the anti-tumorigenic M1 macrophages.
650    _2
$a paklitaxel vázaný na albumin $x terapeutické užití $7 D000068196
650    _2
$a albuminy $x farmakologie $x terapeutické užití $7 D000418
650    _2
$a zvířata $7 D000818
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a HeLa buňky $7 D006367
650    _2
$a lidé $7 D006801
650    _2
$a hydrodynamika $7 D057446
650    _2
$a makrofágy $x účinky léků $x metabolismus $7 D008264
650    _2
$a myši nahé $7 D008819
650    _2
$a nanočástice $x terapeutické užití $7 D053758
650    _2
$a nádory $x farmakoterapie $7 D009369
650    _2
$a paclitaxel $x farmakologie $x terapeutické užití $7 D017239
650    _2
$a velikost částic $7 D010316
650    _2
$a polymery $x chemie $7 D011108
650    _2
$a reaktivní formy kyslíku $x metabolismus $7 D017382
650    _2
$a tkáňová distribuce $x účinky léků $7 D014018
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
700    1_
$a Jäger, Eliézer $u Institute of Macromolecular Chemistry v.v.i, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
700    1_
$a Bagheri Fam, Shahla $u Department of Radiation Biology, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway.
700    1_
$a Höcherl, Anita $u Institute of Macromolecular Chemistry v.v.i, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
700    1_
$a Jäger, Alessandro $u Institute of Macromolecular Chemistry v.v.i, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
700    1_
$a Sincari, Vladimir $u Institute of Macromolecular Chemistry v.v.i, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
700    1_
$a Nyström, Bo $u Department of Chemistry, University of Oslo, Oslo, Norway.
700    1_
$a Štěpánek, Petr $u Institute of Macromolecular Chemistry v.v.i, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
700    1_
$a Skotland, Tore $u Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway.
700    1_
$a Sandvig, Kirsten $u Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway. Department of Biosciences, University of Oslo, Oslo, Norway.
700    1_
$a Hrubý, Martin $u Institute of Macromolecular Chemistry v.v.i, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
700    1_
$a Mælandsmo, Gunhild M $u Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway. Institute of Medical Biology, Faculty of Health Sciences, The Arctic University of Norway - University of Tromsø, Tromsø, Norway.
773    0_
$w MED00176143 $t International journal of nanomedicine $x 1178-2013 $g Roč. 14, č. - (2019), s. 6269-6285
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31496685 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200109 $b ABA008
991    __
$a 20200114152727 $b ABA008
999    __
$a ok $b bmc $g 1482811 $s 1083215
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 14 $c - $d 6269-6285 $e 20190806 $i 1178-2013 $m International journal of nanomedicine $n Int J Nanomedicine $x MED00176143
LZP    __
$a Pubmed-20200109

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...